JNJ-61393215

JNJ-61393215 is an orexin antagonist medication which is under development for the treatment of depression and anxiety disorders.[1][2][3][4] It is an orally active compound and acts as a selective antagonist of the orexin OX1 receptor (1-SORA).[2][3][4] Preliminary clinical findings suggest that JNJ-61393215 may have anti-panic effects in humans.[2][3] As of November 2021, JNJ-61393215 is in phase 2 clinical trials for the treatment of major depressive disorder and is in the preclinical stage of development for treatment of panic disorder, while no further development has been reported for treatment of other anxiety disorders.[1] The drug was originated and developed by Janssen Pharmaceuticals.[1]

JNJ-61393215
Clinical data
Other namesJNJ-3215
Routes of
administration		Oral
Drug classOrexin receptor antagonist
Identifiers
IUPAC name
  • [(1S,4R,6R)-3,3-dideuterio-6-[5-(trifluoromethyl)pyridin-2-yl]oxy-2-azabicyclo[2.2.1]heptan-2-yl]-(3-fluoro-2-pyrimidin-2-ylphenyl)methanone
CAS Number
PubChem CID
ChemSpider
ChEMBL
Chemical and physical data
FormulaC23H18F4N4O2
Molar mass458.417 g·mol−1
3D model (JSmol)
SMILES
  • [2H]C1([C@@H]2C[C@H](N1C(=O)C3=C(C(=CC=C3)F)C4=NC=CC=N4)[C@@H](C2)OC5=NC=C(C=C5)C(F)(F)F)[2H]
InChI
  • InChI=1S/C23H18F4N4O2/c24-16-4-1-3-15(20(16)21-28-7-2-8-29-21)22(32)31-12-13-9-17(31)18(10-13)33-19-6-5-14(11-30-19)23(25,26)27/h1-8,11,13,17-18H,9-10,12H2/t13-,17+,18-/m1/s1/i12D2
  • Key:HUKWIAXQBOHZIX-USKNZQBOSA-N

See also

References
  1. "JNJ 61393215 - AdisInsight".
  2. Caldirola D, Alciati A, Cuniberti F, Perna G (2021). "Experimental Drugs for Panic Disorder: An Updated Systematic Review". J Exp Pharmacol. 13: 441–459. doi:10.2147/JEP.S261403. PMC 8055642. PMID 33889031.
  3. Jacobson LH, Hoyer D, de Lecea L (May 2022). "Hypocretins (orexins): The ultimate translational neuropeptides". J Intern Med. 291 (5): 533–556. doi:10.1111/joim.13406. PMID 35043499. S2CID 248119793.
  4. Salvadore G, Bonaventure P, Shekhar A, Johnson PL, Lord B, Shireman BT, Lebold TP, Nepomuceno D, Dugovic C, Brooks S, Zuiker R, Bleys C, Tatikola K, Remmerie B, Jacobs GE, Schruers K, Moyer J, Nash A, Van Nueten LG, Drevets WC (September 2020). "Translational evaluation of novel selective orexin-1 receptor antagonist JNJ-61393215 in an experimental model for panic in rodents and humans". Transl Psychiatry. 10 (1): 308. doi:10.1038/s41398-020-00937-9. PMC 7477545. PMID 32895369.



This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.